Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Amoeba-biocide.com Start-Up
Volgen
04/12/2020 | 18:11?Amoeba : Amoéba annonce l'émission de la 9° tranche d'obligations convertibles en actions COMMUNIQUE DE PRESSE AMOEBA annonce l'émission de la neuvième tranche de 26 obligations convertibles en actions dans le cadre de son financement obligataire avec programme d'intéressement conclu avec Nice & Green Chassieu (France), le 4 décembre, 2020 - 17h45 - AMOÉBA (FR0011051598 - ALMIB), producteur d'un biocide biologique capable d'éliminer le risque bactérien dans l'eau et les plaies humaines, et d'un produit de biocontrôle pour la protection des plantes, encore en phase de tests, annonce l'émission de la 9ème tranche d'obligations convertibles en actions (les « OCA ») de son financement obligataire avec programme d'intéressement, à savoir 26 OCA numérotées de 209 à 234 intégralement émises au profit de Nice & Green S.A. Cette émission s'inscrit dans le cadre du contrat d'émission conclu avec Nice & Green S.A. le 17 décembre 2019 et d'un avenant n°1 au dit contrat conclu le 9 mars 2020, en vue de la mise en place d'un financement obligataire avec programme d'intéressement par émission de 312 OCA d'une valeur nominale de 20.000 euros chacune représentant un montant nominal total d'emprunt obligataire de 6.240.000 euros (le « Contrat d'Emission »)a. Cette opération a fait l'objet d'un prospectus approuvé par l'AMF (visa n° 20-011) le 16 janvier 2020 (le « Prospectus »). [...] en PDF : www.amoeba-biocide.com/sites/default/...
Amoeba : Amoéba extends to the USA the testing of its biocontrol products with GOWAN COMPANY PRESS RELEASE AMOEBA EXTENDS TO THE U.S.A. THE TESTING OF ITS BIOCONTROL PRODUCTS WITH THE US GROUP GOWAN COMPANY Chassieu (France), December 7, 2020 - 5.45 pm- AMOEBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces the signature of a Material Transfer Agreement (MTA) with GOWAN COMPANY, a leading supplier of agricultural inputs (crop protection products, seeds and fertilizers) in the USA. The purpose of the research partnership is the provision by Amoéba of experimental products containing the amoeba lysate Willaertia magna C2c Maky. In return, GOWAN COMPANY will carry out its own field trials to evaluate the performance of these products in preventing fungal diseases on a range of crops in the US market. Amoéba and GOWAN COMPANY are thus embarking on a targeted research phase, which, if successful, could promote the commercial development of Amoéba biocontrol solutions in the USA "This research partnership with a US company generating more than $500M in revenue materializes the first step in market engagement of Amoéba biocontrol products. It's perfectly aligned with the current assessment of our biocontrol dossier by the US authorities", explains Jean-Luc Souche - Amoéba Biocontrol Business Developer. About GOWAN COMPANY Gowan Company, based in Yuma, Arizona, USA, is a family-owned developer, registrant and marketer of crop protection products, seeds, and fertilizers. Gowan champions technology for agriculture and horticulture through innovative product development, public advocacy and quality production. Gowan's strong commitment to biologicals stems from their steadfast dedication to understanding and anticipating grower needs. About AMOEBA: Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products. Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on Euronext Growth. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.
Vandaag in dubio gestaan maar toch iets anders gekocht. Jammer voor mij mooi nieuws voor jullie
ik las op frans forum reactie op dat PB, die google zo vertaalde: "Test testen testen.....ze lijken nog niet echt bij de poort te staan ??om de toverdrank op de markt te brengen" :)
mercurius-adept schreef op 8 december 2020 09:28 :
ik las op frans forum reactie op dat PB, die google zo vertaalde:
"Test testen testen.....ze lijken nog niet echt bij de poort te staan ??om de toverdrank op de markt te brengen"
:)
Het aandeel loopt nu enkel op verwachtingswaarde, inderdaad. Ik plaats nog maar een keer de tijdlijnen van marktautorisatie. Grove tijdlijnen van vermarkting biologische oplossingen voor de landbouw. (Vanaf mei 2020) Amoéba grapevinedowny mildew (France), August11 2020- the publication of a first scientific article on its biocontrol application(https://www.mdpi.com/2223-7747/9/8/1013/pdf)in the special issue« Natural Products for Plant Pest and Disease Control» ofPlants, journal of theMDPIGroup, peer-reviewed. As a reminder, the marketing of biocontrol products containing this active substance is envisaged by Amoéba in 2024 in Europe (dossier submitted, cf. Press Release of 29 May 2020) and in the first half of 2022 in the United States (submission envisaged in July 2020, cf. Press Release of 29 April 2020, postponed to September 2020). The prioritization of Amoéba's Regulatory Affairs Department resources on biocontrol application leads to a delay in the filing of a new application for biocidal application in the United States, which was envisaged in mid 2020 (see Universal Registration Document of April 30, 2020) and will be submitted at the end of 2020, with first marketing in the United States estimated in the first half of 2022. Amoeba Fungicidal use in agriculture The biocontrol solution, developed by Amoéba, is intended for a fungicidal use in agriculture. A possible approval mid-2023 The dossier submission is in line with Amoébatime schedule. The approval procedure that is starting will take between 2.5 and 3.5 years, with an expected decision in 2023. The main steps are as follows: •Evaluation phase by the rapporteur Member State (approximately 14 months): at the end of which the draft report is submitted to the European Food Safety Authority (EFSA). •Risk assessment phase (7 to 11 months): EFSA carries out the risk assessment and risk communication on food safety aspects and then organises an consultation with experts and publishes a scientific report containing its conclusions. •Risk management phase (9 to 12 months): the European Commission presents a draft regulation to the Standing Committee on the Food Chain and Animal Health, which ultimately votes on the approval or non-approval of the active substance. In general, an active substance is approved for a period of 10 years, or even 15 years if it is classified as "low risk". These timeframes could be reduced depending on the deployment of the “Farm to Fork Strategy” strategy of the European Commission (published on May 20th, 20202) who “will also facilitate the placing on the market of pesticides containing biological active substancesand[...] will act to reduce the length of the pesticide authorisation process by Member States”
Kleintje66 schreef op 7 december 2020 21:49 :
Vandaag in dubio gestaan maar toch iets anders gekocht. Jammer voor mij mooi nieuws voor jullie
Wat heb je dan gekocht? Waarom is dit mooi nieuws voor ons? Je maakt me nieuwsgierig door zo weinig prijs te geven...
Vanwaar de sterke daling ? Is er nieuws ?
Lego schreef op 8 december 2020 13:46 :
Vanwaar de sterke daling ? Is er nieuws ?
Na zo'n ongekende stijging moest er een keer wat lucht uit. Geen nieuws of tegenslag. Voor mij is het belangrijkste dat ie nu boven de 3 euro blijft en derhalve zijn pennystock imago verliest.
MisterBlues schreef op 8 december 2020 10:41 :
[...]
Wat heb je dan gekocht? Waarom is dit mooi nieuws voor ons?
Je maakt me nieuwsgierig door zo weinig prijs te geven...
Ik dacht dat wel positief gereageerd zou worden op het nieuws. Gisteren niet gekocht vanwege de stijgingen de afgelopen tijd. Dat laatste blijkbaar goed ingeschat dat eerste niet.
Amoéba signs an exclusive development and marketing agreement in France with PHILAGRO for its grapevine biocontrol product PRESS RELEASE AMOEBA SIGNS AN EXCLUSIVE DEVELOPMENT AND MARKETING AGREEMENT IN FRANCE WITH PHILAGRO FOR ITS GRAPEVINE BIOCONTROL PRODUCT Chassieu (France), December 9, 2020 - 5.45 pm- AMOEBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces the signature of a Letter of Intent (LOI) with PHILAGRO France, concerning the development and marketing of its biocontrol product against vine downy mildew in France. This signature, with a recognised player in the crop protection market, an entity born from the strategic alliance of three Japanese groups (SUMITOMO Chemical Company, NISSAN Chemical Industries and NIHON NOHYAKU Company), follows on from the partnership announced in April 2020 to evaluate the performance of the biocontrol fungicide containing AMOEBA's active substance: the amoeba lysate Willaertia magna C2c Maky. The aim of the LOI is to define the collaboration outlines between the two companies before and after the marketing of the product on the French territory with a view to signing a commercial partnership contract within 12 months. Amoéba will carry out the regulatory tests necessary for the registration of its product and PHILAGRO will refine the marketing and commercial positioning of the product through field trials. Amoéba has made an exclusive commitment with PHILAGRO France concerning vine application over a marketing period of several years in France, the leading European market for downy mildew treatment. "The Philagro team is delighted to be able to work with Amoéba for the development and future marketing of this very promising biocontrol solution in the strategic segment of the vine downy mildew. The two companies share a common vision of the evolution of the French market and high expectations in biocontrol innovations, complementing each other perfectly to make this solution a real technical and commercial success" explains Denis TROALEN, General Manager of PHILAGRO France. "The choice of PHILAGRO as an exclusive partner is guided by more than 25 years of experience in the service of crop protection, a strong operational positioning in biocontrol and a real capacity for commercial execution in this strategic segment. The human relationship established between our two companies during this 2020 year of field tests has convinced us of the unfailing motivation of the teams to make the most of our product against vine downy mildew in France. "comments Fabrice PLASSON, Chairman and CEO of Amoéba.
Weinig Posts hier voor een aandeel met dit jaar al 500%+
Populaire aandelen zijn wonderbaarlijk niet per se ook echt winstgevende aandelen. (Pharming, Galap.) Waarom doe jij niet wat onderzoek en maak een leuke post hier?
Chassieu (France), December 18, 2020 AMOEBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces the signature of a Term Sheet with STÄHLER SUISSE SA, for the development and marketing of its biocontrol product against vine downy mildew in Switzerland.
MisterBlues schreef op 17 december 2020 09:14 :
Populaire aandelen zijn wonderbaarlijk niet per se ook echt winstgevende aandelen.
(Pharming, Galap.)
Waarom doe jij niet wat onderzoek en maak een leuke post hier?
Heb wat onderzoek gedaan en wat linkjes doorgenomen die hier gepost zijn. lijkt me een mooie aandeel voor de lange termijn. Heb er 900 op de plank gelegd.
AMOEBA RENEWS A FINANCING LINE OF UP TO €23M WITH NICE & GREEN TO SUPPORT ITS DEVELOPMENT Chassieu (France), December 21, 2020 - 5.45 pm- AMOEBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces the signature of a new contract for the issue of bonds convertible into shares with a profit-sharingprogramme (OCAPI) and a subordination agreement between Amoéba, Nice & Green SA and the European Investment Bank (EIB). This new 24-month financing line is intended to give Amoéba the means to finance its key activities, in particular the development of its biocontrol product, and to restructure its debt. www.marketscreener.com/quote/stock/AM...
Wat een dumo vanochtend. Stoplosses af laten gaan?
Koers is dalende.Afwachtende houding....
€URO-Trader schreef op 28 december 2020 23:00 :
Koers is dalende.Afwachtende houding....
Wat is de reden?
Er is gewoon luwte. Logisch dat de koers daalt na zo'n enorme klim, geholpen door KT-handelaren. Het spannende nu is of het blijft hangen rond de drie euro. Het ziet er wel zo uit. Dan kan het aandeel eindelijk een keer het jaar record voorbij als er weer goed nieuws is. (Duurt nog even.)
Dank je, laten we het in de gaten houden, er ontstaan (op termijn) dus instapmomenten, de vraag is wanneer, begrijp ik, MisterBlues.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
860,01
-0,62%
EUR/USD
1,0655
+0,11%
FTSE 100
7.895,85
+0,24%
Germany40^
17.714,20
-0,69%
Gold spot
2.392,50
0,00%
NY-Nasdaq Composite
15.282,01
-2,05%
Stijgers
Dalers